<p><strong>股东权益的增加和票据延期增强了公司的胰腺癌开发战略能力</strong></p>
<p>佛罗里达州奥卡拉，2026 年 5 月 19 日（GLOBE NEWSWIRE）-- <strong>AIM ImmunoTech Inc.</strong> <strong>（纽约证券交易所：AIM）</strong>（“AIM” 或 “公司”）今天宣布股东权益显著增加，并且公司已与 Streeterville Capital, LLC 签署了现有票据协议的修订第 2 号，将到期日延长至 2027 年 6 月 30 日。</p>
<p>截至 2026 年 3 月 31 日，AIM 最近报告的股东权益约为 210 万美元，相较于 2025 年 12 月 31 日约 980 万美元的股东赤字，股东权益显著增加了约 1190 万美元。自 2026 年 3 月 31 日以来，公司还通过各种交易筹集了产生股权的资金。</p>
<p>公司认为，股东权益的增加和票据的延期进一步支持其谨慎管理资本资源的能力，同时保持对近期里程碑的关注，包括继续推进其胰腺癌开发项目和其他旨在最大化长期股东价值的战略举措。</p>
<p>“我们感谢 Streeterville Capital 通过此次延期所表现出的持续支持和信心，” AIM 首席执行官 Thomas Equels 表示。“此次修订在公司重要阶段增强了我们的资本配置灵活性，我们将继续专注于执行我们的临床和运营优先事项。我们相信，未来几个季度将出现多个潜在催化剂，可能创造显著的股东价值，并进一步扩展我们的战略选择。”</p>
<p>根据修订条款，原定于 2024 年 2 月 16 日到期的票据到期日已从之前的到期日延长至 2027 年 6 月 30 日。修订及相关延期费用后，票据的未偿余额约为 168 万美元。</p>
<p><strong>关于 AIM ImmunoTech Inc.</strong></p>
<p>AIM ImmunoTech Inc.是一家免疫制药公司，专注于其主要产品 Ampligen®（rintatolimod）的研究与开发，旨在治疗晚期胰腺癌，这是一种致命且未满足的全球健康问题。Ampligen 是一种双链 RNA 和高度选择性的 TLR3 激动剂免疫调节剂，在临床试验中显示出广谱活性。</p>
<p>欲了解更多信息，请访问 aimimmuno.com，并在 X、LinkedIn 和 Facebook 上与公司联系。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明，这些声明涉及许多风险和不确定性。对于这些声明，公司主张根据 1995 年《私人证券诉讼改革法》提供的前瞻性声明安全港的保护。前瞻性声明可能通过使用 “相信”、“期望”、“打算”、“可能”、“将”、“计划”、“潜在”、“预期” 或类似表达来识别。本文中所列的任何前瞻性声明仅在此日期有效。这些前瞻性声明可能包括与以下内容相关的声明：预期的里程碑；临床试验的开始、招募、完成和结果的时间；执行临床和运营优先事项；知识产权扩展和监管进展；以及获得政府批准的时间（如果有的话）。公司不承诺更新任何这些前瞻性声明，以反映此日期之后发生的事件或情况，除非适用法律要求。公司正在不同阶段寻求确定 Ampligen 是否对多种类型的病毒疾病、癌症和免疫缺陷疾病有效，并且公司向 SEC 提交的报告、其网站上的信息以及其新闻稿中披露了其当前和预期的未来活动。这些活动可能因多种原因而发生变化。需要进行大量额外的测试和试验，以确定 Ampligen®是否对这些疾病的治疗有效。预临床研究获得的结果不一定能预测人类的结果。需要进行人类临床试验以证明 Ampligen®在人体内是否有效。无法保证当前或计划中的临床试验将成功或产生有利的数据，试验受到许多因素的影响，包括缺乏监管批准、缺乏研究药物、缺乏足够的资金或赞助其他试验的机构的优先事项发生变化。即使这些临床试验启动，公司也无法保证临床研究将成功或产生任何有用的数据。无法保证初步研究的发现将被证明是正确的，或这些研究将产生有利的结果，或未来的研究不会得出与公司向 SEC 提交的报告、公司网站和新闻稿中提到的研究不同的发现。在外国开展业务带来了许多风险，包括在执行知识产权方面可能遇到的困难。公司无法保证其潜在的外国业务不会受到这些风险的不利影响。</p>
<p>有关风险因素的详细讨论，请查阅公司最近的 10-K 表格年度报告和随后的 10-Q 表格季度报告中的 “风险因素” 部分。这些文件可在 www.sec.gov 和 www.aimimmuno.com 上获取。公司网站上的信息不被纳入本新闻稿的引用，仅供参考。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qVTVNQ00zTmpBNU56WTBJekl3TWpNeE5qUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qVTVNQ00zTmpBNU56WTBJekl3TWpNeE5qUT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDFkOWVlNzgtM2RlOS00Y2ZkLWEzZmQtMDg2M2VhMGM2OTYzLTEwMzQ3MzUtMjAyNi0wNS0xOS1lbg==/tiny/AIM-ImmunoTech-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDFkOWVlNzgtM2RlOS00Y2ZkLWEzZmQtMDg2M2VhMGM2OTYzLTEwMzQ3MzUtMjAyNi0wNS0xOS1lbg==/tiny/AIM-ImmunoTech-Inc-.png"/></p>
<pre><code> 投资者联系：JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
</code></pre>

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

<p>AIM ImmunoTech Inc. 宣布股东权益显著增加至约 210 万美元，并将其本票的到期日延长至 2027 年 6 月 30 日。这一延长增强了公司的财务灵活性，支持其胰腺癌开发战略。首席执行官对公司管理资本资源和实现近期里程碑的能力表示信心，这可能会创造股东价值</p>

<p><strong>Increase in stockholder equity and note extension strengthen Company’s ability to advance pancreatic cancer development strategy</strong></p>
<div class="lb-trans"><p><strong>股东权益的增加和票据延期增强了公司的胰腺癌开发战略能力</strong></p>
</div><p>OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- <strong>AIM ImmunoTech Inc.</strong> <strong>(NYSE American: AIM)</strong>(“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has entered into Amendment #2 to its existing promissory note agreement with Streeterville Capital, LLC, extending the maturity date to June 30, 2027.</p>
<div class="lb-trans"><p>佛罗里达州奥卡拉，2026 年 5 月 19 日（GLOBE NEWSWIRE）-- <strong>AIM ImmunoTech Inc.</strong> <strong>（纽约证券交易所：AIM）</strong>（“AIM” 或 “公司”）今天宣布股东权益显著增加，并且公司已与 Streeterville Capital, LLC 签署了现有票据协议的修订第 2 号，将到期日延长至 2027 年 6 月 30 日。</p>
</div><p>AIM recently reported stockholder equity of approximately $2.1 million as of March 31, 2026, which is a significant increase of approximately $11.9 million in stockholder equity from the reported stockholder deficit of approximately $9.8 million as of December 31, 2025. The Company has also raised equity-generating funds through various transactions since March 31, 2026.</p>
<div class="lb-trans"><p>截至 2026 年 3 月 31 日，AIM 最近报告的股东权益约为 210 万美元，相较于 2025 年 12 月 31 日约 980 万美元的股东赤字，股东权益显著增加了约 1190 万美元。自 2026 年 3 月 31 日以来，公司还通过各种交易筹集了产生股权的资金。</p>
</div><p>The Company believes the increase in stockholder equity and the note extension further support its ability to prudently manage capital resources while maintaining focus on near-term milestones, including continued advancement of its pancreatic cancer development program and other strategic initiatives intended to maximize long-term stockholder value.</p>
<div class="lb-trans"><p>公司认为，股东权益的增加和票据的延期进一步支持其谨慎管理资本资源的能力，同时保持对近期里程碑的关注，包括继续推进其胰腺癌开发项目和其他旨在最大化长期股东价值的战略举措。</p>
</div><p>“We appreciate the continued support and confidence demonstrated by Streeterville Capital through this extension,” said AIM Chief Executive Officer Thomas Equels. “This amendment enhances our capital allocation flexibility at an important stage for the Company as we remain focused on executing our clinical and operational priorities. We believe the coming quarters present multiple potential catalysts that could create meaningful stockholder value and further expand our strategic optionality.”</p>
<div class="lb-trans"><p>“我们感谢 Streeterville Capital 通过此次延期所表现出的持续支持和信心，” AIM 首席执行官 Thomas Equels 表示。“此次修订在公司重要阶段增强了我们的资本配置灵活性，我们将继续专注于执行我们的临床和运营优先事项。我们相信，未来几个季度将出现多个潜在催化剂，可能创造显著的股东价值，并进一步扩展我们的战略选择。”</p>
</div><p>Under the terms of the amendment, the maturity date of the promissory note originally issued on February 16, 2024, has been extended from its prior maturity to June 30, 2027. Following the amendment and associated extension fee, the outstanding balance of the note is approximately $1.68 million.</p>
<div class="lb-trans"><p>根据修订条款，原定于 2024 年 2 月 16 日到期的票据到期日已从之前的到期日延长至 2027 年 6 月 30 日。修订及相关延期费用后，票据的未偿余额约为 168 万美元。</p>
</div><p><strong>About AIM ImmunoTech Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 AIM ImmunoTech Inc.</strong></p>
</div><p>AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.</p>
<div class="lb-trans"><p>AIM ImmunoTech Inc.是一家免疫制药公司，专注于其主要产品 Ampligen®（rintatolimod）的研究与开发，旨在治疗晚期胰腺癌，这是一种致命且未满足的全球健康问题。Ampligen 是一种双链 RNA 和高度选择性的 TLR3 激动剂免疫调节剂，在临床试验中显示出广谱活性。</p>
</div><p>For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 aimimmuno.com，并在 X、LinkedIn 和 Facebook 上与公司联系。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “believes,” “expects,” “intends,” “may,” “will,” “plans,” “potential,” “anticipates,” or similar expressions. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating to: anticipated milestones; the timing of commencement, enrollment, completion, and results of clinical trials; executing clinical and operational priorities; IP expansion and regulatory progress; and timing for receiving government approvals, if at all. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明，这些声明涉及许多风险和不确定性。对于这些声明，公司主张根据 1995 年《私人证券诉讼改革法》提供的前瞻性声明安全港的保护。前瞻性声明可能通过使用 “相信”、“期望”、“打算”、“可能”、“将”、“计划”、“潜在”、“预期” 或类似表达来识别。本文中所列的任何前瞻性声明仅在此日期有效。这些前瞻性声明可能包括与以下内容相关的声明：预期的里程碑；临床试验的开始、招募、完成和结果的时间；执行临床和运营优先事项；知识产权扩展和监管进展；以及获得政府批准的时间（如果有的话）。公司不承诺更新任何这些前瞻性声明，以反映此日期之后发生的事件或情况，除非适用法律要求。公司正在不同阶段寻求确定 Ampligen 是否对多种类型的病毒疾病、癌症和免疫缺陷疾病有效，并且公司向 SEC 提交的报告、其网站上的信息以及其新闻稿中披露了其当前和预期的未来活动。这些活动可能因多种原因而发生变化。需要进行大量额外的测试和试验，以确定 Ampligen®是否对这些疾病的治疗有效。预临床研究获得的结果不一定能预测人类的结果。需要进行人类临床试验以证明 Ampligen®在人体内是否有效。无法保证当前或计划中的临床试验将成功或产生有利的数据，试验受到许多因素的影响，包括缺乏监管批准、缺乏研究药物、缺乏足够的资金或赞助其他试验的机构的优先事项发生变化。即使这些临床试验启动，公司也无法保证临床研究将成功或产生任何有用的数据。无法保证初步研究的发现将被证明是正确的，或这些研究将产生有利的结果，或未来的研究不会得出与公司向 SEC 提交的报告、公司网站和新闻稿中提到的研究不同的发现。在外国开展业务带来了许多风险，包括在执行知识产权方面可能遇到的困难。公司无法保证其潜在的外国业务不会受到这些风险的不利影响。</p>
</div><p>For a detailed discussion of risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. These filings are available at www.sec.gov and www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference into this press release and is included for reference purposes only.</p>
<div class="lb-trans"><p>有关风险因素的详细讨论，请查阅公司最近的 10-K 表格年度报告和随后的 10-Q 表格季度报告中的 “风险因素” 部分。这些文件可在 www.sec.gov 和 www.aimimmuno.com 上获取。公司网站上的信息不被纳入本新闻稿的引用，仅供参考。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU1qVTVNQ00zTmpBNU56WTBJekl3TWpNeE5qUT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMjU5MCM3NjA5NzY0IzIwMjMxNjQ="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDFkOWVlNzgtM2RlOS00Y2ZkLWEzZmQtMDg2M2VhMGM2OTYzLTEwMzQ3MzUtMjAyNi0wNS0xOS1lbg==/tiny/AIM-ImmunoTech-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MDFkOWVlNzgtM2RlOS00Y2ZkLWEzZmQtMDg2M2VhMGM2OTYzLTEwMzQ3MzUtMjAyNi0wNS0xOS1lbg==/tiny/AIM-ImmunoTech-Inc-.png"/></p>
<pre><code>Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
</code></pre>
<div class="lb-trans"><pre><code> 投资者联系：JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
</code></pre>
</div>

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities | AIM Stock News

StockTitan

AIM ImmunoTech

医疗业 ETF - Vanguard

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

Invesco Nasdaq Biotechnology ETF

标普全球医疗股指数 ETF - iShares

美国制药 ETF - iShares

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

AIM ImmunoTech 宣布股东权益显著增加，并将本票到期日延长至 2027 年 6 月，以增强财务灵活性并支持战略临床优先事项 | AIM 股票新闻